Howard Welgus Net Worth

The estimated Net Worth of Howard G. Welgus is at least $2.71 Millón dollars as of 3 September 2024. Howard Welgus owns over 10,000 units of Arcutis Biotherapeutics Inc stock worth over $2,019,251 and over the last 5 years he sold ARQT stock worth over $691,434. In addition, he makes $0 as Director at Arcutis Biotherapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Howard Welgus ARQT stock SEC Form 4 insiders trading

Howard has made over 46 trades of the Arcutis Biotherapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of ARQT stock worth $107,700 on 3 September 2024.

The largest trade he's ever made was exercising 19,861 units of Arcutis Biotherapeutics Inc stock on 4 February 2021 worth over $33,366. On average, Howard trades about 3,995 units every 31 days since 2020. As of 3 September 2024 he still owns at least 191,944 units of Arcutis Biotherapeutics Inc stock.

You can see the complete history of Howard Welgus stock trades at the bottom of the page.

Howard Welgus biography

Dr. Howard G. Welgus M.D. has been appointed as Director of the Company effective 8/1/2020. From February 2016 to June 2018, Dr. Welgus served as the Chief Medical Officer at Verrica Pharmaceuticals Inc. Prior to joining Verrica, Dr. Welgus served as the Chief Medical Officer at Thesan Pharmaceuticals Inc. from September 2012 to November 2016 and served as the Chief Medical Officer at Nycomed US Inc. from May 2009 to November 2010. From 1999 to 2009, he served as the Vice President and head of the Dermatology and Inflammation therapeutic areas in Discovery at Pfizer Inc. in Ann Arbor, MI. Prior to joining the private sector, Dr. Welgus was a faculty member at Washington University for 17 years. Dr. Welgus is a board-certified dermatologist and received a M.D. from Washington University School of Medicine in St. Louis and a B.A. in Biology from Rice University.

How old is Howard Welgus?

Howard Welgus is 68, he's been the Director of Arcutis Biotherapeutics Inc since 2020. There are no older and 27 younger executives at Arcutis Biotherapeutics Inc.

What's Howard Welgus's mailing address?

Howard's mailing address filed with the SEC is C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91361.

Insiders trading at Arcutis Biotherapeutics Inc

Over the last 5 years, insiders at Arcutis Biotherapeutics Inc have traded over $33,184,604 worth of Arcutis Biotherapeutics Inc stock and bought 3,754,945 units worth $71,202,175 . The most active insiders traders include Jonathan Silverstein, Patrick J Heron y Advisors Llcorbimed Capital.... On average, Arcutis Biotherapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $361,425. The most recent stock trade was executed by Howard G. Welgus on 3 September 2024, trading 10,000 units of ARQT stock currently worth $107,700.

What does Arcutis Biotherapeutics Inc do?

arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.

Complete history of Howard Welgus stock trades at Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc executives and stock owners

Arcutis Biotherapeutics Inc executives and other stock owners filed with the SEC include:

• Todd Watanabe,
  President, Chief Executive Officer, Director
• Kenneth Lock,
  Chief Commercial Officer
• Todd Franklin Watanabe M.A.,
  Pres, CEO & Director
• Patricia Turney,
  Senior Vice President - Manufacturing
• Dr. Patrick E. Burnett M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Kenneth A. Lock,
  Chief Commercial Officer
• Bhaskar Chaudhuri,
  Independent Director
• Joseph Turner,
  Independent Director
• Ricky Sun,
  Independent Director
• Jonathan Silverstein,
  Independent Director
• Howard Welgus,
  Director
• Halley Gilbert,
  Director
• Terrie Curran,
  Director
• Patrick Burnett,
  Chief Medical Officer
• Keith Klein,
  General Counsel
• Frank Pompilio,
  Vice President - Medical Affairs
• Lynn Navale,
  Vice President - Biometrics
• Charlotte Merritt,
  Vice President - Regulatory Affairs
• Ayisha Jeter,
  Vice President of Market Access
• Meg Elias,
  Vice President - Clinical Operations
• Bethany Dudek,
  Vice President - Quality
• David Berk,
  Vice President - Clinical Development
• Heather Armstrong,
  Vice President of Investor Relations and Corporate Communications
• Kimberly Lathroum,
  Vice President of Marketing
• Jay Ramsinghani,
  Vice President of Commercial Strategy and Operations
• Scott Burrows,
  Vice President - Finance
• John Smither,
  Chief Financial Officer
• David Osborne,
  Co-Founder, Chief Technical Officer
• Patrick Heron,
  Independent Chairman of the Board
• Masaru Matsuda Esq., J.D.,
  Gen. Counsel & Corp. Sec.
• Courtney Barton,
  Chief Compliance Officer, VP, Chief of Staff & Chief Privacy Officer
• Eric McIntyre,
  Head of Investor Relations
• Dr. David W. Osborne,
  Chief Technical Officer
• Patricia A. Turney,
  Sr. VP of Operations
• Scott L. Burrows,
  CFO & Principal Accounting Officer
• Larry Todd Edwards,
  SVP Chief Commercial Officer
• Daniel Estes,
  Director
• Neha Krishnamohan,
  Director
• David Joseph Topper,
  Chief Financial Officer
• Masaru Matsuda,
  See Remarks
• Capital Life Sciences Inves...,
  
• Advisors Llcorbimed Capital...,
  
• Life Sciences Viii, L.P.Fhm...,
  
• Matthew Richard Moore,
  SVP and Chief Business Officer
• Life Sciences Viii, L.P.Fhm...,
  
• Sue Jean Lin,
  Director
• Keith R Leonard,
  Director
• Life Sciences Viii, L.P.Fhm...,